INTerpath-009 Trial Expands V940 Clinical Program, Targeting Earlier Cancer Stages
Merck (NYSE: MRK), known as MSD in markets outside the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), have announced the launch of INTerpath-009, a pivotal Phase 3 randomized clinical trial assessing V940 (mRNA-4157), an investigational individualized neoantigen therapy,…